Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Shares of Eli Lilly LLY and Novo Nordisk NVO were up on Tuesday, likely due to a proposal by President Biden that Medicare ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The stock's early-sessions lows when it was down more than ... That news sent the stocks of market leaders Novo Nordisk A/S (NVO) and Eli Lilly & Co. (LLY) higher, along with Viking Therapeutics Inc. ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Shares in Danish drug maker Novo Nordisk have increased following President Biden's ... that Novo's share movement coincided with similar trends in the market, as Eli Lilly, a U.S. competitor, also ...

The Biden administration is proposing a rule that would require the U.S. government to cover weight-loss drugs, potentially expanding access for millions of Americans with obesity and creating ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over one year for patients who were obese or overweight without diabetes. In ...

MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight ...

Amgen Inc. announced on Tuesday that its experimental weight-loss drug, MariTide, demonstrated an average weight reduction of ...

The Biden administration is proposing a rule that would require Medicare and Medicaid to cover weight-loss drugs, potentially ...

Amgen released promising results from its Phase 2 trial, but the data led to a significant decline in its stock price as Wall ...